NCT01125761撤回3 期
Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Through clinical examinations, evaluating the efficacy of the cream composed by 0.5 mg dexamethasone and clemastine 1mg compared with the cream of 0.5 mg dexamethasone in improving the signs and symptoms associated with allergic dermatitis.
研究概览
简要总结
Considering the pathogenesis of several allergic skin diseases to be investigated in this study as well as the pharmacodynamic mechanisms of the association of dexamethasone and clemastine fumarate, it is believed that the components of topical medication may act synergistically in the reduction of signs and symptoms of the diseases in question. Therefore it is expected that the association promotes results significantly superior to dexamethasone alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who sign the Deed of Consent (IC) in two ways, by his own free will, agreeing with all study procedures;
- •Patients older than 18 years, any ethnicity, class or social group, regardless of sex;
- •Patients with pictures of dermatoses acute, subacute or chronic, of inflammatory origin and / or allergic, to which it is recommended the use of drugs under investigation topically, such as:
- •atopic dermatitis,
- •primary contact dermatitis or allergic
- •urticaria,
- •pharmacodermic,
- •allergic vasculitis,
- •dyshidrosis,
排除标准
- •Patients being treated with antibiotics;
- •Participation in clinical trials in the 12 months preceding the survey;
- •Current treatment with immunosuppressants (eg, cyclosporine or methotrexate);
- •Current treatment with phototherapy (UVA, UVB, PUVA and lasers);
- •Use of systemic corticosteroids at inclusion visit or within 15 days prior to inclusion;
- •Topical treatments at the site of acne in the 15 days preceding the visit of inclusion;
- •Presence of any skin condition in areas affected by acne that hamper the evolutionary analysis of the lesion;
- •Presence of secondary infections at the site of treatment, diagnosed clinically;
- •Presence of other eczematous picture, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome Wiskott-Aldrich;
- •Pregnant or lactating women;
- •Chronic alcoholism;
- •Patients with a history of hypersensitivity to any component of the formulas of the products under investigation;
- •Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study;
- •Allergic Dermatosis of moderate or severe that, according to the investigator, is not justified topical.
研究组 & 干预措施
dexamethasone 0.5 mg and 1.0 mg clemastine cream
Experimental
干预措施: dexamethasone 0.5 mg and 1.0 mg clemastine cream (Drug)
dexamethasone 0,5 mg cream
Active Comparator
干预措施: Dexamethasone 0,5 mg cream (Drug)
结局指标
主要结局
Through clinical examinations, evaluating the efficacy of the cream composed by 0.5 mg dexamethasone and clemastine 1mg compared with the cream of 0.5 mg dexamethasone in improving the signs and symptoms associated with allergic dermatitis.
时间窗: 14 days
次要结局
- Evaluate, through clinical examinations, the effectiveness of the drug association in reducing excoriation associated with allergic dermatitis.(14 days)
- Improvement of the erythema associated with allergic dermatitis.(14 days)
- Improvement of the edema associated with allergic dermatitis.(14 days)
- Improvement of the extension of lesion associated with allergic dermatitis.(14 days)
- Evaluate, through clinical examinations, the effectiveness of the drug association in reducing exudation associated with allergic dermatitis.(14 dyas)
- Evaluate, through clinical examinations, the effectiveness of the drug association in reducing of scabbing associated with allergic dermatitis.(14 days)
- Evaluate, through clinical examinations, the effectiveness of the drug association in reducing of lichenification associated with allergic dermatitis.(14 days)
- Evaluate the safety of the formulations in relation to the occurrence, type, frequency and intensity of adverse events during treatment.(14 days)
研究者
Azidus Brasil
Principal Investigator Dr. Alexandre Frederico
Azidus Brasil
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Clinical study on allergic factors of SI-613/ONO-5704Osteoarthritis of knee and hip with history of administration of SI-613 / ONO-5704JPRN-jRCT1040220009ishida Yoshihiro27
招募中
1 期
Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of AnaphylaxisAnaphylaxisNCT03523221Hamad Medical Corporation210
招募中
2 期
LAssa Fever Adjunct Treatment With DEXamethasoneLassa FeverNCT06222723Bernhard Nocht Institute for Tropical Medicine42
已完成
4 期
Effect of Topical Dexamethasone on Histologic Response of Human Dental PulpVital Pulp TherapyNCT02574468Isfahan University of Medical Sciences10
尚未招募
不适用
Spironolactone on COVID-19 patients.CTRI/2021/03/031721one